CanSino Biologics Inc.
http://www.cansinotech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CanSino Biologics Inc.
China Lays Out Requirements For Biosimilar Extrapolation
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
Two New Vaccines Join COVID Fight As China Ships Millions Overseas
CanSino's adenovirus-based COVID-19 vaccine, along with another one from state-owned Sinopharm grab promot approvals in China as Beijing shipping millions of doses around the world.
When The Mighty Fall, Smaller Vaccine Players Seize The COVID Day
While global vaccine heavyweights Merck & Co, Sanofi and GSK are so far not faring so well to successfully develop a vaccine for COVID-19, smaller players are stepping up. That's especially true for segmented markets such as China.
One Year On: WHO Concludes Wuhan Probe; CanSino Vaccine 66% Effective
A WHO team concludes a high-profile investigation in Wuhan, where the first coronavirus cases surfaced over a year ago, while a single-dose vaccine from China's CanSino is on the way.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Tianjin CanSino Biotechnology